NBP
NovaBridge Biosciences NASDAQ$2.38
After hrs
$2.41
+0.42%
Mkt Cap $227.9M
52w Low $0.83
26.0% of range
52w High $6.79
50d MA $2.80
200d MA $3.67
P/E (TTM)
-5.0x
EV/EBITDA
-26.3x
P/B
0.1x
Debt/Equity
0.0x
ROE
-20.0%
P/FCF
-129.4x
RSI (14)
—
ATR (14)
—
Beta
1.74
50d MA
$2.80
200d MA
$3.67
Avg Volume
810.5K
About
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 7, 2026 | AMC | -0.01 | -0.03 | -528.3% | 2.48 | +5.6% | -1.2% | -2.0% | -4.8% | -3.2% | +2.4% | — | — |
| Dec 18, 2025 | AMC | -0.01 | -0.25 | -1801.5% | 3.96 | +0.5% | +5.8% | +10.9% | +13.6% | +16.9% | +9.6% | -1.0% | — |
| Nov 12, 2025 | AMC | -0.04 | -0.01 | +76.5% | 4.22 | -0.9% | -1.2% | -1.7% | +3.6% | +7.6% | +7.3% | -5.5% | — |
| May 15, 2025 | AMC | -0.06 | -0.04 | +33.3% | 0.89 | -3.1% | +1.7% | +2.9% | +3.2% | +6.6% | +18.6% | +184.7% | — |
| Apr 4, 2025 | AMC | -0.06 | -0.11 | -83.3% | 0.68 | +13.2% | -8.8% | +0.9% | +1.3% | -0.9% | -1.6% | +25.7% | — |
| Nov 14, 2024 | AMC | -0.16 | -0.25 | -56.2% | 1.07 | +1.9% | -2.8% | -5.6% | -10.9% | -8.4% | -10.4% | -10.3% | — |
| Aug 28, 2024 | AMC | -0.51 | -0.07 | +86.3% | 1.17 | +0.9% | -4.3% | -3.4% | -10.3% | -10.3% | -10.3% | -1.7% | — |
| Jun 5, 2024 | AMC | — | 0.04 | — | 1.90 | +0.5% | -1.6% | -1.1% | -2.1% | -2.1% | -2.6% | -15.8% | — |
| Mar 29, 2024 | AMC | -0.10 | -0.59 | -513.0% | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.57 | — | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.48 | $2.62 | +5.6% | -1.2% | -2.0% | -4.8% | -3.2% | +2.4% |
| Mar 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.83 | $3.10 | +9.5% | +2.5% | +1.8% | -0.4% | -4.9% | -9.5% |
| Feb 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.33 | $3.47 | +4.2% | +11.1% | +4.2% | +2.7% | +1.8% | -2.7% |
| Oct 24 | BTIG | Maintains | Buy → Buy | — | $4.39 | $4.40 | +0.2% | -3.9% | +7.1% | +5.7% | +5.5% | +3.6% |
| Oct 17 | BTIG | Maintains | Buy → Buy | — | $6.56 | $6.30 | -4.0% | -12.0% | -20.4% | -21.8% | -26.5% | -33.1% |
| Sep 10 | BTIG | Maintains | Buy → Buy | — | $4.60 | $4.25 | -7.6% | -9.1% | -15.2% | -11.1% | -21.3% | -19.1% |
| Sep 8 | Needham | Maintains | Buy → Buy | — | $4.38 | $4.43 | +1.1% | -2.5% | +5.0% | -4.6% | -11.0% | -6.6% |
| Aug 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.52 | $4.38 | -3.1% | +4.2% | +12.6% | +6.6% | +14.6% | -0.4% |
| Aug 20 | Needham | Maintains | Buy → Buy | — | $4.21 | $4.15 | -1.4% | +7.4% | +11.9% | +20.9% | +14.5% | +23.0% |
| Jul 9 | Needham | Maintains | Buy → Buy | — | $2.20 | $2.22 | +0.9% | +5.0% | -6.8% | -3.2% | -2.7% | -4.5% |
Data updated apr 26, 2026 2:21pm
· Source: massive.com